Cell and gene therapy products are used for treatment of various genetic disorders and chronic diseases. The therapy involves modifying genes or cells that are being introduced into patient's body, to treat disease or to repair cells. Cell and gene therapy products are used for treatment of cancer, neurological disorders, cardiovascular disease, infectious diseases and other genetic disorders. The therapy holds potential to permanently cure genetic disorders by correcting faulty genes or by introducing new genes. Scientific advancements in gene editing technologies such as CRISPR/Cas9 have accelerated development of cell and gene therapy products.

The global cell and gene therapy Market is estimated to be valued at US$ 18.29 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics
Scientific advancements in gene editing technologies along with increasing focus on development of personalized medicine is expected to drive growth of the global cell and gene therapy market over the forecast period. CRISPR/Cas9 technology has emerged as promising gene editing tool for development of cell and gene therapies. This technology allows precise editing of genes without affecting surrounding DNA sequences. Increasing applications of CRISPR technology is expected to boost market growth. Furthermore, rising prevalence of cancer and other chronic diseases along with increasing regulatory approvals for cell and gene therapy products will also contribute to market growth over the forecast period. However, high costs associated with cell and gene therapy products and ethical issues related to gene editing and cell modifications can hamper market growth.

SWOT Analysis

Strength: The cell and gene therapy market offers promising therapeutic solutions for various genetic disorders, cancers and chronic diseases. Advanced therapies such as CAR T-cell and gene therapies have shown significant success in clinical trials against difficult-to-treat cancers. Growing support from regulatory bodies in order to fast track development of advanced therapies is further fueling innovation.

Weakness: High costs associated with the development of cell and gene therapies make these treatments unaffordable for majority of patients globally. Technical challenges pertaining to efficient and stable delivery also add to production costs. Regulatory compliance and risk of product failure remain key roadblocks.

Opportunity: Large patient pools of rare and orphan indications present lucrative opportunities for targeted therapies. Emerging economies in Asia Pacific offer high growth potential owing to rising healthcare spending and increasing adoption. Partnerships between pharma companies and clinical research organizations can help accelerate clinical research.

Threats: Safety concerns over viral vectors and risk of tumor formation remain major challenges. Commercialization challenges posed by infrastructure requirements for these complex treatments threaten timely market access. stringent regulations may delay approvals.


Key Takeaways

The Global Cell And Gene Therapy Market Size is expected to witness high growth over the forecast period owing to advancing pipeline and rising number of approvals. Faster adoption in the

North America region is expected owing to strong government support and presence of top market players. The US market is anticipated to dominate led by advanced scientific research capabilities and availability of reimbursements for new therapies. Growing burden of cancer and other chronic diseases is further supporting market growth in the region.

Europe is also positioned for high growth supported by increasing R&D investments from key players and streamlined regulatory pathways for advanced therapies in countries such as the UK. However, Asia Pacific region is emerging as a highly lucrative market driven by large patient pools, rising healthcare spending and rapid establishment of clinical trial infrastructure.

Key players related content comprises: Key players operating in the cell and gene therapy market are Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., CORESTEM Inc., Dendreon Pharmaceuticals LLC., Helixmith Co. Ltd., JCR Pharmaceuticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, Pfizer Inc. These players are focusing on expanding their pipeline through collaborations and acquisitions to strengthen their market position.

For More Insights, Read: https://www.trendingwebwire.com/cell-and-gene-therapy-market-trends-growth-and-regional-outlook-2023-2030/